Effect of long-term administration of prostaglandin I2 in incipient diabetic nephropathy

Nephron

Volumn 92, Issue 4, 2002, Pages 788-796

  Owada, Akira ^a,b   Suda, Shin ^a   Hata, Toshihiko ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b NONE   (Japan)

Author keywords

Beraprost sodium; Hypertension; Microalbuminuria; Protein intake; Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; BERAPROST; GLUCOSE; PROSTACYCLIN DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFORMED CONSENT; LONG TERM CARE; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY EXCRETION;

AGED; ALBUMINURIA; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIETARY PROTEINS; EPOPROSTENOL; FEMALE; HEMOGLOBIN A; HUMANS; LIPIDS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0036969949     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065445     Document Type: Article

References (25)

1. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M: PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 1995;48:111-117.
2. Haider A, Oh P, Peloso PM: An evidence-based review of ACE inhibitors in incipient diabetic nephropathy. Can J Clin Pharmacol 2000;7:115-119.
3. Arima S, Ren YL, Juncos LA, Carretero OA, Ito S: Glomerular prostaglandins modulate vascular reactivity of the downstream efferent arterioles. Kidney Int 1994;45:650.
4. Craven PA, Caines MA, DeRubertis FR: Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: Relationship to the hyperfiltration of early diabetes. Metabolism 1987;36:95-103.
5. Masumura H, Kunitada S, Irie K, Ashida S, Abe Y: A thromboxaneA2 synthetase inhibitor retards hypertensive rat diabetic nephropathy. Eur J Pharmacol 1992;210:163-172.
6. Feldt-Rasmussen B, Mathiesen ER, Hegedus L, Deckert T: Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy. N Engl J Med 1986;314:665-670.
7. The Kroc Collaborative Study Group: Blood glucose control and the evolution of diabetic retinopathy and albuminuria: A preliminary multicenter trial. N Engl J Med 1984;311:365-372.
8. Feldt-Rasmussen B, Mathiesen ER, Deckert T: Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986;ii: 1300-1304.
9. The Euclid Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-1792.
10. Christensen CK, Mogensen CE: Anthypertensive treatment: Long-term reversal of progression of albuminuria in incipient diabetic nephropathy: A longitudinal study of renal function. Complications 1987;1:45-52.
11. Melbourne Diabetic Nephropathy Study Group: Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991;302:210-216.
12. Pedersen MM, Winther E, Mogensen CE: Reducing protein in the diabetic diet. Diabéte Métabol (Paris) 1990;16:454-459.
13. Cohen D, Dodds R, Viberti G: Effect of protein restriction in insulin dependent diabetics at risk of nephropathy. BMJ 1987;294:795-798.
14. Brouhard BH, Lagrone L: Effect of dietary protein restriction on functional renal reserve in diabetic nephropathy. Am J Med 1990;89: 427-431.
15. Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985;27:58-65.
16. Moorthead JF: Lipids and progressive kidney disease. Kidney Int 1991;39(suppl 31):S35-S40.
17. Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP: Hyperlipidemia and progressive renal disease. Kidney Int 1991;39:S41-S48.
18. Keane WF: Lipids and the kidney. Kidney Int 1994;46:910-920.
19. Parving HH, Osterby R, Anderson PW, Hsueh WA: Diabetic nephropathy; in Brenner BM (ed): The Kidney, ed 5. Philadelphia, Saunders, 1996, pp 1864-1892.
20. Koh E, Morimoto S, Jiang B, Inoue T, Nabata T, Kitano S, Yasuda O, Fukuo K, Ogihara T: Effects of beraprost sodium, a stable analogue of prostacyclin, on hyperplasia, hypertrophy and glycosaminoglycan synthesis of rat aortic smooth muscle cells. Artery 1993;20:242-252.
21. Villa E, Pabano A, Ruilope LM, Garcia-Robles R: Effects of cicaprost and fosinopril on the progression of rat diabetic nephropathy. Am J Hypertens 1997;10:202-208.
22. 2 analog beraprost sodium on glomerular prostanoid synthesis in rats with streptozotocin-induced diabetes. Nephron 1996;73:637-643.
23. Harrison HE, Reece AH, Johnson M: Decreased vascular prostacyclin in experimental diabetes. Life Sci 1978;23:351-356.
24. Gragnoli G, Signorini AM, Tanganelli I, Fon-delli C, Borgogni P, Borgogni L, Vattimo A, Ferrari F, Guercia M: Prevalence of glomerular hyperfiltration and nephromegaly in normo-and microalbuminuric type 2 diabetic patients. Nephron 1993;65:206-211.
25. Craven PA, Melhem MF, Derubertis FR: Thromboxane in the pathogenesis of glomerular injury in diabetes. Kidney Int 1992;42:937-946.